Tags

Type your tag names separated by a space and hit enter

PaxVax CVD 103-HgR single-dose live oral cholera vaccine.
Expert Rev Vaccines. 2017 03; 16(3):197-213.ER

Abstract

INTRODUCTION

Cholera remains a problem in developing countries and a risk for travelers. Hypochlorhydria, blood group O, cardiac and renal disease increase the risk of developing cholera gravis. Oral vaccines containing inactivated Vibrio cholerae and requiring two doses are available in some countries. No cholera vaccine had been available for U.S. travelers for decades until 2016 when CVD 103-HgR (VAXCHORA™), an oral live attenuated vaccine, was licensed by the U.S. FDA. Areas covered: Enduring protection following wild-type cholera provided the rationale to develop a single-dose live oral vaccine. CVD 103-HgR is well-tolerated and protects against cholera caused by V. cholerae O1 of either serotype (Inaba, Ogawa) and biotype (El Tor, Classical). Since 90% vaccine efficacy is evident 10 days post-ingestion of a single dose, CVD 103-HgR can rapidly protect travelers. Vibriocidal antibody seroconversion correlates with protection; >90% of U.S. adult (including elderly) vaccinees seroconvert. The U.S. Public Health Service's Advisory Committee on Immunization Practices recommends CVD 103-HgR for U.S. travelers to areas of ongoing cholera transmission. Expert commentary: Next steps include evaluations in children, post-licensure safety and effectiveness monitoring, diminishing cold chain constraints, optimizing a 'high-dose' formulation for developing countries, and diminishing/eliminating the need for water to administer a dose.

Authors+Show Affiliations

a Center for Vaccine Development , University of Maryland School of Medicine , Baltimore , MD , U.S.A.a Center for Vaccine Development , University of Maryland School of Medicine , Baltimore , MD , U.S.A.b Department of Microbiology and Immunology , University of Maryland School of Medicine , Baltimore , MD , U.S.A.c PaxVax, Inc. , Redwood City , CA.c PaxVax, Inc. , Redwood City , CA.c PaxVax, Inc. , Redwood City , CA.

Pub Type(s)

Journal Article
Review
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

28165831

Citation

Levine, Myron M., et al. "PaxVax CVD 103-HgR Single-dose Live Oral Cholera Vaccine." Expert Review of Vaccines, vol. 16, no. 3, 2017, pp. 197-213.
Levine MM, Chen WH, Kaper JB, et al. PaxVax CVD 103-HgR single-dose live oral cholera vaccine. Expert Rev Vaccines. 2017;16(3):197-213.
Levine, M. M., Chen, W. H., Kaper, J. B., Lock, M., Danzig, L., & Gurwith, M. (2017). PaxVax CVD 103-HgR single-dose live oral cholera vaccine. Expert Review of Vaccines, 16(3), 197-213. https://doi.org/10.1080/14760584.2017.1291348
Levine MM, et al. PaxVax CVD 103-HgR Single-dose Live Oral Cholera Vaccine. Expert Rev Vaccines. 2017;16(3):197-213. PubMed PMID: 28165831.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - PaxVax CVD 103-HgR single-dose live oral cholera vaccine. AU - Levine,Myron M, AU - Chen,Wilbur H, AU - Kaper,James B, AU - Lock,Michael, AU - Danzig,Lisa, AU - Gurwith,Marc, PY - 2017/2/7/pubmed PY - 2017/8/17/medline PY - 2017/2/7/entrez KW - Cholera KW - cholera vaccines KW - live oral vaccine KW - travelers’ vaccines KW - vaccine SP - 197 EP - 213 JF - Expert review of vaccines JO - Expert Rev Vaccines VL - 16 IS - 3 N2 - INTRODUCTION: Cholera remains a problem in developing countries and a risk for travelers. Hypochlorhydria, blood group O, cardiac and renal disease increase the risk of developing cholera gravis. Oral vaccines containing inactivated Vibrio cholerae and requiring two doses are available in some countries. No cholera vaccine had been available for U.S. travelers for decades until 2016 when CVD 103-HgR (VAXCHORA™), an oral live attenuated vaccine, was licensed by the U.S. FDA. Areas covered: Enduring protection following wild-type cholera provided the rationale to develop a single-dose live oral vaccine. CVD 103-HgR is well-tolerated and protects against cholera caused by V. cholerae O1 of either serotype (Inaba, Ogawa) and biotype (El Tor, Classical). Since 90% vaccine efficacy is evident 10 days post-ingestion of a single dose, CVD 103-HgR can rapidly protect travelers. Vibriocidal antibody seroconversion correlates with protection; >90% of U.S. adult (including elderly) vaccinees seroconvert. The U.S. Public Health Service's Advisory Committee on Immunization Practices recommends CVD 103-HgR for U.S. travelers to areas of ongoing cholera transmission. Expert commentary: Next steps include evaluations in children, post-licensure safety and effectiveness monitoring, diminishing cold chain constraints, optimizing a 'high-dose' formulation for developing countries, and diminishing/eliminating the need for water to administer a dose. SN - 1744-8395 UR - https://www.unboundmedicine.com/medline/citation/28165831/PaxVax_CVD_103_HgR_single_dose_live_oral_cholera_vaccine_ L2 - http://www.tandfonline.com/doi/full/10.1080/14760584.2017.1291348 DB - PRIME DP - Unbound Medicine ER -